NKGen Biotech Inc Stock Price, News & Analysis

NKGen Biotech (OTC:NKGN) will present at the XXVII World Congress of Neurology in Seoul, South Korea on October 12–15, 2025. CEO Paul Y. Song, M.D., will deliver a presentation on troculeucel, an investigational autologous enhanced natural killer (NK) cell therapy for moderate/advanced Alzheimer’s disease.

The talk, titled "Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Moderate/Advanced Alzheimer’s Disease. Scientific Rationale with Preliminary Clinical and Biomarker Results," is scheduled for October 15, 2025 at 11:50 AM KST in Conference Room North 201 during the Free Paper – Ataxia and Cerebellar Disorders & Dementia session. A copy of the presentation will be posted under the company’s Scientific Publications page after the event.

NKGen Biotech (OTC: NKGN), a clinical-stage biotech company, will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou on September 25-26, 2025. CEO Paul Y. Song will discuss their investigational NK cell therapy, troculeucel, for neurodegenerative diseases.

The presentation will take place at the Sino-Singapore Guangzhou Knowledge City International Convention Center on September 25, 2025, at 3:20 PM CST. The forum will host over 1,200 experts and 90 speakers, focusing on cell and gene therapy, RNA therapeutics, and stem cell research.

NKGen Biotech (OTC: NKGN) has successfully completed the acquisition of a 65% controlling stake in NKMax Co., Ltd. for $16.9 million. The strategic transaction, funded by AlpineBrook Capital GP 1 Limited and CEO Dr. Paul Y. Song, transforms NKGen into a fully integrated cell therapy company with complete control over global manufacturing infrastructure and intellectual property assets.

The acquisition marks a significant turnaround for NKGen, which faced challenges after NKMax's bankruptcy in 2024 and its own delisting from Nasdaq. The deal secures NKMax's operations through 2026 and positions NKGen to advance its lead therapeutic candidate, troculeucel, which has received FDA fast track designation and shown promising results in over 90% of Alzheimer's patients treated to date.

NKGen Biotech (OTC:NKGN), a clinical-stage biotech company, will present at the 13th Annual Immuno-Oncology Summit in Philadelphia from August 11-13, 2025. CEO Paul Y. Song will discuss their allogeneic NK cell therapy, SNK02, which uniquely treats solid tumors without requiring lymphodepletion.

The presentation, scheduled for August 13, 2025, at 2:50 PM ET, will focus on NK cells' role in fighting cancer and showcase scientific data and early clinical findings. SNK02 represents a potential advancement in cancer treatment by avoiding the immunologic compromises typically associated with traditional allogeneic therapies.

NKGen Biotech (OTC:NKGN) presented groundbreaking Phase 1 data for troculeucel, their innovative NK cell therapy for Alzheimer's disease, at AAIC 2025. The therapy demonstrated remarkable efficacy with 92% of patients (12 out of 13) showing stable or improved cognitive function after three months.

Key findings revealed that troculeucel can cross the blood-brain barrier and exhibits multiple mechanisms of action, including reduction of neuroinflammation and ability to degrade both amyloid and α-synuclein proteins. Notably, two out of three moderate AD patients receiving the highest dose improved to mild-stage AD, maintaining improvement through one year of treatment.

The treatment showed dose-dependent improvements in CSF biomarkers, with 100% of high-dose patients showing improvements in CSF α-synuclein levels after six months, while maintaining stable Aβ42/40 ratio and p-Tau 181 levels.

NKGen Biotech (OTC: NKGN) announced its upcoming presentation at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto, Canada from July 27-31, 2025. The company will present a poster detailing the mechanism of action of troculeucel, their enhanced non-genetically modified NK cell therapy for Alzheimer's disease.

The presentation by Dr. Paul Y. Song will take place on Sunday, July 27, 2025, from 7:30 AM to 4:15 PM ET in the Exhibit Hall. The poster will include Phase I biomarker data and will be available on NKGen's website after the presentation.

NKGen Biotech (OTC: NKGN) has received FDA authorization for an Expanded Access Program (EAP) for troculeucel, its autologous enhanced natural killer cell therapy. The authorization allows treatment of up to 20 patients with various neurodegenerative diseases, expanding beyond their current Phase 2a Alzheimer's trial.

The EAP will include patients with early-stage Alzheimer's, Parkinson's, ALS, Multiple System Atrophy, Progressive Supranuclear Palsy, Frontotemporal Dementia, Corticobasal degeneration, Multiple Sclerosis, and Lewy Body Dementia. Troculeucel has shown preliminary clinical benefits without drug-related adverse events in two Phase I Alzheimer's trials, demonstrating ability to cross the blood-brain barrier and reduce neuroinflammatory markers.

NKGen Biotech (OTC: NKGN) has formed a strategic partnership with HekaBio to accelerate the development and commercialization of troculeucel, their autologous NK cell therapy, in Japan. The partnership follows HekaBio's recent equity investment in NKGen.

HekaBio will spearhead clinical trials and regulatory activities in Japan for troculeucel, targeting neurodegenerative diseases including Alzheimer's and Parkinson's. Under Japan's Regenerative Medicine guidelines, which offer expedited commercialization paths, HekaBio aims to begin patient dosing within 12 months.

The therapy shows potential for both treating intractable neurodegenerative diseases and supporting Japan's aging population in the longevity/wellness space.

NKGen Biotech (OTC: NKGN) has secured $2 million in funding from a Japanese strategic investor through a common equity PIPE with warrants priced at $0.25 per share. The funding aims to help the company regain compliance with reporting obligations and listing standards after facing challenges from its former parent company NKMax's bankruptcy in June 2024.

The company's stock will temporarily move to the OTC Expert Market, limiting trading accessibility, with plans to uplist to OTCQB once SEC filings are current. NKGen is developing troculeucel, an NK cell therapy for Alzheimer's and neurodegenerative diseases, and is currently ramping up its Phase 2 clinical trial. The company expects to acquire a majority stake in NKMax, consolidating key IP rights across Asia, and aims to eventually return to Nasdaq or NYSE American listing.